Yahoo
NYSE - Delayed Quote USD

CONMED Corporation (CNMD)

44.29 -1.43 (-3.13%)
At close: October 30 at 4:00:02 PM EDT
44.29 0.00 (0.00%)
After hours: October 30 at 4:01:09 PM EDT
Trade CONMED on Coinbase
Chart Range Bar
Loading chart for CNMD
  • Previous Close 45.72
  • Open 45.71
  • Bid 42.00 x 10000
  • Ask 46.72 x 10000
  • Day's Range 43.67 - 46.10
  • 52 Week Range 31.44 - 53.66
  • Volume 404,075
  • Avg. Volume 385,169
  • Market Cap (intraday) 1.32B
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) 18.38
  • EPS (TTM) 2.41
  • Earnings Date (est.) Jan 27, 2027
  • Forward Dividend & Yield 0.80 (0.00%)
  • 1y Target Est 46.83
  • Zacks Rating Neutral

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solutions comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures; and products to treat diseases of dilation, hemostasis, biliary, stricture management, and infection prevention, as well as ECG electrodes, EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

www.conmed.com

3,900

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNMD
9.09%
S&P 500 (^GSPC)
10.73%

1-Year Return

CNMD
0.45%
S&P 500 (^GSPC)
11.11%

3-Year Return

CNMD
53.54%
S&P 500 (^GSPC)
81.91%

5-Year Return

CNMD
68.55%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 335.56M
Earnings 19.8M
Profit Margin 5.90%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
100M
200M
300M
4.5%
5.0%
5.5%
6.0%
6.5%

Analyst Insights

View More

Analyst Price Targets

43.00 Low
46.83 Average
44.29 Current
50.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/29/2026
Analyst JP Morgan
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 45 -> 50

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.36%

  • Return on Assets (ttm)

    3.79%

  • Return on Equity (ttm)

    7.10%

  • Revenue (ttm)

    1.37B

  • Net Income Avi to Common (ttm)

    73.43M

  • Diluted EPS (ttm)

    2.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    47.97M

  • Total Debt/Equity (mrq)

    76.97%

  • Levered Free Cash Flow (ttm)

    107.01M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: